放射性药剂学

Radiopharmaceuticals are synthesized to target specific organs or cells in the body for diagnostic or therapeutic purposes.
放射性药物被合成，用于靶向身体内的特定器官或细胞，以达到诊断或治疗目的。
The most common radiopharmaceutical used in positron emission tomography (PET) is fluorodeoxyglucose (FDG).
在正电子发射断层扫描（PET）中最常见的放射性药物是氟代脱氧葡萄糖（FDG）。
Technetium-99m is a widely employed radioisotope in radiopharmaceuticals due to its short half-life and favorable properties for imaging.
钯-99m因其半衰期短和适合成像的特性，在放射性药物中被广泛应用。
Radiolabeled antibodies are an example of targeted radiopharmaceuticals, enabling precise cancer therapy.
标记抗体是靶向放射性药物的一个例子，可实现精确的癌症治疗。
Bone scans often use radiopharmaceuticals like sodium fluoride to detect bone abnormalities.
骨扫描常常使用如氟化钠之类的放射性药物来检测骨骼异常。
Radiopharmaceuticals are administered intravenously, allowing them to be distributed throughout the body for diagnostic imaging.
放射性药物通常静脉注射，以便它们能在体内分布，用于诊断成像。
Ablative radiopharmaceuticals, like yttrium-90, can be used to treat certain types of cancer by delivering targeted radiation.
消耗性放射性药物，如钇-90，可用于治疗某些类型的癌症，通过精确投放辐射。
The development of new radiopharmaceuticals is an ongoing area of research, with the goal of improving treatment outcomes and reducing side effects.
新放射性药物的研发是一个持续的研究领域，目标是提高治疗效果并减少副作用。
Pharmacokinetics studies are crucial in understanding how radiopharmaceuticals are absorbed, distributed, metabolized, and eliminated from the body.
药物动力学研究对于理解放射性药物如何被吸收、分布、代谢和从体内排出至关重要。
The safety and efficacy of radiopharmaceuticals are strictly regulated by health authorities before they can be prescribed to patients.
在放射性药物被处方给患者之前，其安全性和有效性必须严格受到卫生部门的监管。